{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:18:42Z","timestamp":1790929122019,"version":"4.1.0"},"reference-count":157,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Medicinal Research Reviews"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Since 2013, a rapidly expanding portfolio of U.S. Food and Drug Administration (FDA)\u2010approved drugs has highlighted pyrimidine as one of the most versatile and therapeutically valuable heteroaromatic scaffolds. Building on more than six decades of medicinal chemistry, these recent approvals underscore the pivotal role of pyrimidines in modern drug discovery across oncology, anti\u2010infectives, immunology, immuno\u2010oncology, neurological disorders, chronic pain, and metabolic diseases. This review systematically surveys pyrimidine\u2010containing drugs approved from 2013 to the present, detailing their synthetic strategies, key biological targets, and disease\u2010specific mechanisms of action. This review demonstrates the enduring value of pyrimidine as a privileged chemotype and bioisostere for phenyl and other aromatic \u03c0\u2010systems, offering insights to guide the design of next\u2010generation therapeutics for conditions once considered intractable.<\/jats:p>","DOI":"10.1002\/med.70027","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:07:02Z","timestamp":1763705222000},"page":"713-748","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["FDA\u2010Approved Pyrimidine\u2010Containing Drugs: Synthesis and Clinical Application"],"prefix":"10.1002","volume":"46","author":[{"given":"Yao","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0934-7249","authenticated-orcid":false,"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1114-2963","authenticated-orcid":false,"given":"Yanke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery The First Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery The First Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-8918","authenticated-orcid":false,"given":"Zhenhua","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology Shengjing Hospital of China Medical University Shenyang Liaoning China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010104"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2024.216285"},{"key":"e_1_2_7_4_1","first-page":"283","article-title":"The Influence of Bioisosteres in Drug Design: Tactical Applications to Address","volume":"9","author":"Na M.","year":"2014","journal-title":"Tactics in Contemporary Drug Design"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0MD00227E"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/cbdd.14001"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026622666220111143949"},{"key":"e_1_2_7_8_1","article-title":"Pyrimidine\u2010Based Scaffolds: Emerging Frontiers in Antimicrobial Drug Discovery","volume":"10","author":"Alagarsamy V.","year":"2025","journal-title":"Chemistry Europe"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129992"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-54490-3_14"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2054"},{"key":"e_1_2_7_12_1","unstructured":"X.Xu Process for Preparation of Dabrafenib via Sulfonamidation Halogenation Thiazole Cyclization Acetylation and Pyrimidine Cyclization (Suzhou Miracpharma Technology Co. Ltd. 2014) US Patent CN1035887672014."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14676"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190020961291"},{"key":"e_1_2_7_15_1","unstructured":"F.\u2010J.Mais J.Rehse W.Joentgen andK.Siegel Preparation of Pyrimidine Derivatives for Treatment of Cardiovascular Disorders or Erectile Dysfunction (Bayer Schering Pharma Aktiengesellschaft 2011) US Patent US201101304102021."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-025-00692-8"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2015.1000859"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S173050"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.5339\/gcsp.2014.20"},{"key":"e_1_2_7_20_1","first-page":"1675","article-title":"Safety, Efficacy, and Clinical Utility of Macitentan in the Treatment of Pulmonary Arterial Hypertension","volume":"10","author":"Monaco T. J.","year":"2016","journal-title":"Drug Design, Development and Therapy"},{"key":"e_1_2_7_21_1","unstructured":"S.Abele J.\u2010A.Funel andI.Schindelholz Preparation of Pyrimidine Intermediates Useful for the Manufacture of Macitentan (Actelion Pharmaceuticals Ltd. 2014) US Patent WO20141553042014."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3157"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0251-3"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.006"},{"key":"e_1_2_7_25_1","unstructured":"X.Xu Process for the Preparation of Ceritinib and Its Intermediate 2\u2010Isopropoxy\u20105\u2010Methyl\u20104\u2010(Piperidine\u20104\u2010yl)Halobenzene (Suzhou Miracpharma Technology Co. Ltd. 2014) US Patent CN1039922622014."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1185"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0379-9"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1159\/000447001"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312268"},{"key":"e_1_2_7_30_1","unstructured":"B. P.ChekalandN. D.Ide Preparation of Acetylcyclopentylmethylpiperazinylpyridinylaminopyridopyrimidinone Derivatives for Use as Selective cdk4\/6 Inhibitors (Pfizer Inc. 2014) US Patent WO20141285882014."},{"key":"e_1_2_7_31_1","unstructured":"D. T.Erdman C. M.Flamme andJ. D.Nelson Preparation of 2\u2010(Pyridin\u20102\u2010ylamino)\u2010Pyrido[2 3\u2010d]Pyrimidin\u20107\u2010Ones (Pfizer Products Inc. 2008) US Patent WO20080321572008."},{"key":"e_1_2_7_32_1","first-page":"257","article-title":"Osimertinib, Recent Results in Cancer Research","volume":"211","author":"Malapelle U.","year":"2018","journal-title":"Fortschritte der Krebsforschung Progres dans les Recherches sur le Cancer"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0533-4"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1039\/C7MD90012K"},{"key":"e_1_2_7_35_1","unstructured":"M.Ji Y.Li H.Liu R.Li J.Cai andH.Hu Synthetic Method of N\u2010[2\u2010[[2\u2010(Dimethylamino)ethyl]methylamino]\u20104\u2010Methoxy\u20105\u2010[[4\u2010(1\u2010Methyl\u20101H\u2010Indol\u20103\u2010yl)\u20102\u2010Pyrimidinyl]Amino]Phenyl]\u20102\u2010Acrylamide as Antitumor Drug (Suzhou Southeast Pharmaceuticals Co. Ltd. 2015) US Patent CN1048175412015."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2018.54.7.2834460"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0737-x"},{"key":"e_1_2_7_38_1","unstructured":"TELEHEART Telotristat Ethyl in a Heart Biomarker Study (2021) https:\/\/clinicaltrials.gov\/study\/NCT04810091."},{"key":"e_1_2_7_39_1","unstructured":"A.Devasagayaraj H.Jin Z.\u2010C.Shi A.Tunoori Y.Wang andC.Zhang Preparation of 4\u2010[6\u2010(2 2 2\u2010Trifluoro\u20101\u2010Phenylethoxy)Pyrimidin\u20104\u2010yl]\u2010(S)\u2010Phenylalanine Derivatives as Tryptophan Hydroxylase Inhibitors (Lexicon Pharmaceuticals Inc. 2008) US Patent WO20080739332008."},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0776-3"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0569"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-023-01284-w"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.07.008"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108424"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00505"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810171"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.08.010"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b00306"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0838-6"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S142264"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00802-9"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019833992"},{"key":"e_1_2_7_53_1","unstructured":"M.Hentemann J.Wood W.Scott et al. Preparation of Substituted 2 3\u2010Dihydroimidazo[1 2\u2010c]Quinazoline Derivatives for Treating Hyper\u2010Proliferative Disorders and Diseases Associated With Angiogenesis (Bayer Pharmaceuticals Corporation 2008) US patent WO20080701502008."},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0840-z"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1097\/OP9.0000000000000054"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0095"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.015"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tetlet.2014.12.082"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0963-x"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908075"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30497-2"},{"key":"e_1_2_7_64_1","unstructured":"S.Huang X.Jin Z.Liu et al. Preparation of Sulfonamidophenylimidazolylpyrimidine Derivatives and Analogs for Use as Protein Kinase Inhibitors (IRM LLC Novartis A.\u2010G. 2011) US Patent WO20110259272011."},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0927-1"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25125"},{"key":"e_1_2_7_67_1","unstructured":"S.Bhamidipati R.Singh T.Sun andE.Masuda Prodrug Salts of 2 4\u2010Pyrimidinediamine Compounds and Their Preparation and Biological Use (Rigel Pharmaceuticals Inc. 2008) US Patent WO20080642742008."},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S267001"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01205-x"},{"key":"e_1_2_7_70_1","unstructured":"J. J.Cao J.Hood D.Lohse et al. Preparation of Bi\u2010Aryl 2 4\u2010Pyrimidinediamines as Inhibitors of Kinases (TargeGen Inc. 2007) US Patent WO 20070534522007."},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01276-1"},{"key":"e_1_2_7_72_1","doi-asserted-by":"crossref","unstructured":"Lemborexant for Insomnia Australian Prescriber45 no.1(2022):29\u201330.","DOI":"10.18773\/austprescr.2021.046"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.64719\/pb.4483"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03439-8"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.08.034"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00217"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01275-2"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200339"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200339"},{"key":"e_1_2_7_80_1","unstructured":"Y.Zhang B. L.Hodous J. L.Kim K. J.Wilson andD.Wilson Compositions Containing Substituted Pyrrolotriazines Useful for Treating Disorders Related to KIT and PDGF\u2010R (Blueprint Medicines Corporation 2015) US Patent WO20150578732015."},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01427-4"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0967"},{"key":"e_1_2_7_83_1","unstructured":"J. D.Brubaker J. L.Kim K. J.Wilson D.Wilson andL. V.Dipietro Preparation of Heterocyclyl Aminopyrazoles as Inhibitors of RET Kinase for the Treatment of Cancer (Blueprint Medicines Corporation 2017) US Patent US201701213122017."},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01496-z"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13677"},{"key":"e_1_2_7_86_1","unstructured":"J.\u2010P.Stasch E.\u2010M.Becker H.Truebel andH.Himmel Preparation of Pyrimidine Derivatives as Stimulators and Activators of Soluble Guanylate Cyclase for Treating Sickle\u2010Cell Anemia and Conserving Blood Substitutes (Bayer Pharma Aktiengesellschaft 2011) US Patent WO2011161099."},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01317-9"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-023-01378-z"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1566"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-022-04441-3"},{"key":"e_1_2_7_91_1","unstructured":"D.Dorsch F.Stieber O.Schadt andA.Blaukat Pyridazinone Derivatives as Met Kinase Inhibitors and Their Preparation and Use in the Treatment of Cancer (Merck Patent 2009) US Patent WO20090069592009."},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01567-1"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112641"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm2006222"},{"key":"e_1_2_7_95_1","unstructured":"G.Bold P.Furet andV.Guagnano Preparation of Pyrimidinyl Aryl Urea Derivatives as FGF Inhibitors for the Treatment of Protein Kinase Dependent Diseases (Novartis AG 2012) US Patent US82937462012."},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01632-9"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100105"},{"key":"e_1_2_7_98_1","unstructured":"Green Preparation of Mobocertinib Drug for Lung Cancer (Shanghai Tin Tsz Bio Valley Biological Engineering Co. Ltd. 2023) US Patent CN1169870652023."},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01718-y"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2022.2112565"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S51253"},{"key":"e_1_2_7_102_1","unstructured":"S.Blanchard C. H. A.Lee H. K. M.Nagaraj et al. Preparation of Oxygen Linked Pyrimidine Macrocyclic Derivatives as Antiproliferative Agents (S*bio Pte Ltd. 2007) US patent WO20070586272007."},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01839-y"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107886"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02752"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA8509"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.2c04266"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01895-4"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1337436"},{"key":"e_1_2_7_110_1","unstructured":"P. A.Fernandes Gomes dos Santos K.Hoegenauer G.Hollingworth et al. Preparation of Tetrahydropyridopyrimidine Derivatives for Use as PI3K Eenzyme Activity Modulators (Novartis AG 2013) US Patent WO20130014452013."},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01975-5"},{"issue":"8","key":"e_1_2_7_112_1","first-page":"1120","article-title":"Gepirone","volume":"2","author":"Leslie R. A.","year":"2001","journal-title":"Current Opinion in Investigational Drugs (London, England: 2000)"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1177\/87551225241269179"},{"key":"e_1_2_7_114_1","unstructured":"D. L.Temple 2\u2010[4\u2010([4 4\u2010Dialkyl\u20102 6\u2010Piperidinedion\u20101\u2010yl]Butyl)\u20101\u2010Piperazinyl]pyrimidines and Pharmaceutical Compositions Containing the (Bristol\u2010Myers Co. 1983) US Patent DE32481601983."},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01964-8"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01637-7"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01252-1"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01252-1"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01029-3"},{"key":"e_1_2_7_120_1","unstructured":"C. J.Burns A.Spencer andK. A.Monaghan Multiple Myeloma Treatment (Y. M. BioSciences Australia Pty. Ltd. 2012) US Patent WO20121496022012."},{"key":"e_1_2_7_121_1","unstructured":"C. J.Burns A.Spencen andK. A.Monaghan Multiple Myeloma Ttreatment (Ym Biosciences Australia Pty. Ltd. 2014) US Patent US201401714332014."},{"key":"e_1_2_7_122_1","unstructured":"B.Lv Z.Sheng andB.Cao Deuterated (Phenylamino)Pyrimidine Compounds as JAK Kinase Inhibitors and Their Preparation Pharmaceutical Ccompositions and Use in the Treatment of Diseases (Suzhou Zelgen Biopharmaceuticals Co. Ltd. 2014) US patent WO20141142742014."},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02053-0"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2022-0010"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm3009103"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0451"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02069-6"},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3439"},{"key":"e_1_2_7_129_1","unstructured":"W.Chen J.Cossrow L.Franklin et al. Pyrimidine\u20104\u2010Carboxamide Compounds Useful as Raf Kinase Inhibitors and Their Preparation and Use in the Treatment of Raf\u2010mediated Diseases (Sunesis Pharmaceuticals Inc. 2009) US Patent WO2009006389200."},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1372810"},{"key":"e_1_2_7_131_1","volume-title":"Deuruxolitinib, Drugs and Lactation Database (LactMed\u00ae)","author":"NCBI","year":"2006"},{"key":"e_1_2_7_132_1","volume-title":"LiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury","year":"2012"},{"key":"e_1_2_7_133_1","unstructured":"R. S.Lewis M. R.Karla K. E.Kavouris Y.Dong A. J.Morgan andC. J.Cowden Process for Preparing Enantiomerically Enriched JAK Inhibitors (Concert Pharmaceuticals Inc. 2022) US Patent US20220213105."},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01533-x"},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-024-01388-1"},{"key":"e_1_2_7_136_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00515"},{"key":"e_1_2_7_137_1","unstructured":"S.\u2010H.Oh J.\u2010H.Khoo J.\u2010C.Lim et al. Improved Process for Preparing Lazertinib and Intermediates Thereof (Yuhan Corporation 2019) US Patent WO20190224852019."},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02161-5"},{"key":"e_1_2_7_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-05812-3"},{"key":"e_1_2_7_140_1","unstructured":"S.Cacatian D. A.Claremon L. W.Dillard et al. Preparation of Inhibitors of the Menin\u2010MLL Interaction (Vitae Pharmaceuticals Inc. 2017) US Patent WO20172143672017."},{"key":"e_1_2_7_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104896"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01727"},{"key":"e_1_2_7_143_1","unstructured":"M. L.Boys B. D.Ellis J. J.Gaudino et al. Pyrimido[5 4\u2010d]Pyrimidine Derivatives as HER2 Mutation Inhibitors (Array BioPharma Inc. 2022) US Ppatent WO20220035752022."},{"key":"e_1_2_7_144_1","unstructured":"B.Wilding D.Boese H.Engelhardt et al. Synthesis of Diazino\u2010Pyrimidines as Anticancer Agents (Boehringer Ingelheim International GmbH 2021) US Patent WO20212138002021."},{"key":"e_1_2_7_145_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2025.2498477"},{"key":"e_1_2_7_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01556-3"},{"key":"e_1_2_7_147_1","unstructured":"H.Yoshino T.Komoda Y.Shiro S.Murata S.Murata andY.Kuroda Process for the Preparation of Sepiapterin Lactoylpterin and Tetrahydrolactoylpterin (Shiratori Pharmaceutical Co. Ltd. 2013) US Patent WO20131686932013."},{"key":"e_1_2_7_148_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2479126"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01027-4"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.008"},{"key":"e_1_2_7_151_1","unstructured":"S.Noji M.Shiozaki T.Miura et al. Preparation of Nitrogen\u2010Containing Spiro\u2010Ring Compounds as Janus kinase (JAK) Kinase Inhibitors (Japan Tobacco Inc. 2011) US Patent WO20110137852011."},{"key":"e_1_2_7_152_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02215-8"},{"key":"e_1_2_7_153_1","unstructured":"M.Murakata T.Ikeda andT.Ichige Method for Producing Coumarin Derivative (Chugai Seiyaku Kabushiki Kaisha 2013) US Patent WO20130357542013."},{"key":"e_1_2_7_154_1","unstructured":"M. J.Luzzio C. L.Autry S. K.Bhattacharya et al. Preparation of Sulfonyl Amide Derivatives for the Treatment of Abnormal Cell Growth (Pfizer Products Inc. 2008) US Patent WO20081293802008."},{"key":"e_1_2_7_155_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02191-z"},{"key":"e_1_2_7_156_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-21-0361"},{"key":"e_1_2_7_157_1","unstructured":"D. L.Flynn B. D.Smith R. R.Soto andK.Kuida CSF1R Inhibitors for Use in Treating Cancer such as Tenosynovial Giant Cell Tumor (Deciphera Pharmaceuticals LLC 2020) US Patent WO20201398282020."},{"key":"e_1_2_7_158_1","unstructured":"Y.Ahn L.Vogeti T. M.Caldwell M. D.Kaufman andD. L.Flynn Preparation of Pyrimidine Derivatives as Anti\u2010Cancer and Anti\u2010Proliferative Agents (Deciphera Pharmaceuticals LLC 2014) US Patent WO20141450252014."}],"container-title":["Medicinal Research Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70027","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/med.70027","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/med.70027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T07:34:10Z","timestamp":1775633650000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/med.70027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/med.70027"],"URL":"https:\/\/doi.org\/10.1002\/med.70027","archive":["Portico"],"relation":{},"ISSN":["0198-6325","1098-1128"],"issn-type":[{"value":"0198-6325","type":"print"},{"value":"1098-1128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"2025-09-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}